IKT INHIBIKASE THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, INHIBIKASE THERAPEUTICS INC reported revenue of $0, net income of −$19.6M and diluted EPS of −$0.11; for the fiscal year ended December 2025 revenue was n/a.

IKT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$52.0M, net income −$48.3M (margin n/a), EPS −$0.49
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$28.6M, net income −$27.5M (margin n/a), EPS −$1.16
• Fiscal year ended Dec 2023: revenue $261K, gross profit n/a, operating income −$20.1M, net income −$19.0M (margin -7304.7%), EPS −$3.16
• Fiscal year ended Dec 2022: revenue $123K, gross profit n/a, operating income −$18.1M, net income −$18.1M (margin -14625.9%), EPS −$4.28
• Fiscal year ended Dec 2021: revenue $3.10M, gross profit n/a, operating income −$14.8M, net income −$14.8M (margin -476.9%), EPS −$0.81

IKT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $0, net income −$19.6M, EPS −$0.11
• Quarter ended Mar 31, 2026: revenue $0, net income −$16.4M, EPS −$0.10
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$12.7M, EPS −$0.10
• Quarter ended Sep 30, 2025: revenue $0, net income −$11.9M, EPS −$0.13
• Quarter ended Jun 30, 2025: revenue $0, net income −$9.92M, EPS −$0.11
• Quarter ended Mar 31, 2025: revenue $0, net income −$13.7M, EPS −$0.15
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (down 100.0% year over year), net income −$12.1M, EPS $0.88
• Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$5.78M, EPS −$0.65
• Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$4.96M, EPS −$0.66
• Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$4.65M, EPS −$0.73
• Quarter ended Dec 31, 2023 (from the annual report): revenue $1 (down 100.0% year over year), net income −$4.18M, EPS −$0.21
• Quarter ended Sep 30, 2023: revenue $79.6K (up 991.3% year over year), net income −$4.60M, EPS −$0.86
• Quarter ended Jun 30, 2023: revenue $116K (up 1676.7% year over year), net income −$5.78M, EPS −$1.11
• Quarter ended Mar 31, 2023: revenue $64.5K (up 40.2% year over year), net income −$4.48M, EPS −$0.98
• Quarter ended Dec 31, 2022 (from the annual report): revenue $63.6K (up 3169.9% year over year), net income −$4.28M, EPS −$1.94
• Quarter ended Sep 30, 2022: revenue $7.29K (down 97.8% year over year), net income −$4.49M, EPS −$1.06
• Quarter ended Jun 30, 2022: revenue $6.55K (down 99.5% year over year), net income −$4.64M, EPS −$1.10
• Quarter ended Mar 31, 2022: revenue $46.0K (down 96.7% year over year), net income −$4.64M, EPS −$0.18
• Quarter ended Dec 31, 2021 (from the annual report): revenue $1.94K, net income −$5.04M, EPS −$0.15
• Quarter ended Sep 30, 2021: revenue $328K, net income −$4.47M, EPS −$0.18

IKT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$27.8M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$19.1M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$18.1M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$17.4M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$14.3M, share buybacks n/a

IKT balance sheet

• Jun 30, 2026: cash n/a, total assets $164M, total liabilities $10.3M, shareholders' equity $153M
• Mar 31, 2026: cash n/a, total assets $173M, total liabilities $5.71M, shareholders' equity $168M
• Dec 31, 2025: cash $179M, total assets $181M, total liabilities $8.30M, shareholders' equity $173M
• Sep 30, 2025: cash n/a, total assets $79.6M, total liabilities $6.70M, shareholders' equity $72.9M
• Jun 30, 2025: cash n/a, total assets $88.9M, total liabilities $8.80M, shareholders' equity $80.1M
• Mar 31, 2025: cash n/a, total assets $94.3M, total liabilities $8.55M, shareholders' equity $85.7M
• Dec 31, 2024: cash $97.5M, total assets $98.6M, total liabilities $3.73M, shareholders' equity $94.9M
• Sep 30, 2024: cash n/a, total assets $4.38M, total liabilities $4.91M, shareholders' equity −$531K

Is IKT profitable?

No. INHIBIKASE THERAPEUTICS INC lost $60.6M over the last four quarters.

What is IKT's EPS?

Diluted earnings per share over the last four quarters were −$0.44; −$0.11 in the latest quarter.

IKT ownership and insider trades · All stocks